Navigation Links
Agendia Launches TargetPrint(R) for Breast Cancer Patients

Optimizing Patient Identification for Targeted Therapies

That Ensure Benefits of Personalized Treatment HUNTINGTON BEACH, Calif., and AMSTERDAM, Netherlands, Sept. 4 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint(R), a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor Receptor 2 (HER2) in breast cancer tumor biopsies. The accurate measurement of these receptors is of paramount importance in planning treatment of breast cancer patients after surgery and assists physicians and patients in making informed treatment decisions. TargetPrint runs on Agendia's new High Density Chip, which received market clearance last month (August 2008) from the U.S. Food and Drug Administration (FDA).

"Currently available targeted therapies, such as hormone treatments, can have a huge impact on the survival and quality of life of a significant number of breast cancer patients," said Bernhard Sixt, Ph.D., president and chief executive officer of Agendia. "TargetPrint will play a key role in defining which patients are most likely to benefit from these treatments."

"The test's results give a precise molecular read-out of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient," said Richard A. Bender, MD, FACP, chief medical officer of Agendia. "In the near future, it is our plan to add information on a wider range of drug targets to TargetPrint and clinically validate these with key customers."

Agendia will present clinical data on TargetPrint at The 2008 Breast Cancer Symposium which is co-sponsored by the American Society of Clinical Oncology (ASCO) and will be held in Washington, DC from September 5-7, 2008. TargetPrint is processed at Agendia's Clinical Laboratory Improvement Amendments (CLIA) certified and the College of American Pathology (CAP) accredited laboratory.

About Agendia

Agendia is a world leader in molecular cancer diagnostics. The company markets four products based on its breakthrough platform for tumor gene expression profiling and has several new diagnostic tests under development. Agendia was the first company to receive FDA clearance for a breast cancer test, MammaPrint(R), that predicts the risk of breast cancer recurrence. In addition, the company collaborates with pharma companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information on Agendia, please visit


U.S. Media Contact: EU and non-U.S. Media:

Kelly Connor Hans Herklots

Vice President Head Corporate Communications

Ogilvy Public Relations Worldwide Agendia

+1.212.880.5328 Office +31.20.462.1557 Office

+1.609.221.5785 Mobile +31.620.083.509 Mobile

SOURCE Agendia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aon eSolutions Launches Clinical Trials Module
2. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
3. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
4. Impliant Launches Less-Invasive Version of Patented TOPS(TM) Spine System
5. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
6. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
9. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
10. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):